December 12, 2016
Novartis combination against age-related vision loss fails tests
Novartis was denied bringing its eye drug combination of pegpleranib and Lucentis out of Phase III study for age-related vision…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Novartis
December 8, 2016
Novartis gets eye disease drug European approval
European Commission (EC) has granted an additional indication for Novartis’s Lucentis (ranibizumab) to treat patients with eye disease due to…
December 8, 2016
Novartis gets positive COPD related study results
Novartis on Wednesday announced positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequently exacerbating…
November 1, 2016
Novartis gets FDA Priority Review for first-line treatment of advanced breast cancer
Novartis gets FDA Priority Review for first-line treatment of HR+/HER2-advanced breast cancer
October 26, 2016
Novartis CEO sees tougher U.S. drug pricing over next three-five years
Novartis expects a more difficult pricing environment for drugs in…
October 25, 2016
Novartis’s Q3 2016 net income $10,9B shorter than last year
Novartis’s Q3 2016 net income $10,9B shorter than last year
October 9, 2016
Novartis: exploring Zykadia’s efficacy in ALK+ NSCLC patients grows
Novartis today announced updated results from a Phase II study (ASCEND-3), which demonstrated that anaplastic lymphoma kinase-positive (ALK+) non-small cell…
October 8, 2016
Novartis: LEE011 plus letrozole for advanced breast cancer better than standard
Novartis has announced today that results from the pivotal Phase III MONALEESA-2 study show LEE011 (ribociclib) plus letrozole significantly extended…
March 7, 2016
Lilly and Novartis reveal separate studies on plaque psoriasis
Good news for patients with moderate-to-severe plaque psoriasis. In only two days two big pharmaceutical companies have issued press releases about…
December 10, 2015
Rhizen and Novartis enter deal for PI3K delta gamma inhibitor
Rhizen Pharmaceuticals has entered into an exclusive, worldwide agreement with Novartis for the development and commercialization of Rhizen’s inhaled dual PI3K-delta gamma inhibitor and its closely related compound for various indications.